Former Madrigal executive accuses company of retaliation after raising Rezdiffra safety concerns
A former top executive at Madrigal Pharmaceuticals has sued the company in federal court, alleging he was pushed out after raising internal concerns about the safety of its approved medicine for MASH, the liver disease formerly known as metabolic dysfunction-associated steatohepatitis. The complaint places the company’s flagship drug, Rezdiffra, at the center of a dispute over scientific integrity, internal disclosure, and whistleblower protection.
Michael Charlton, a physician who served as Madrigal’s senior vice president and head of clinical development from October 2024 until January 2026, filed the lawsuit in the Northern District of Illinois on Oct. 9. He is seeking reinstatement or monetary damages and accuses the company of retaliation under federal whistleblower-protection statutes.
The filing frames the dispute as a clash between drug safety oversight and corporate pressure.
A lawsuit built around internal safety objections
Charlton’s complaint says his role carried a clear mandate: protect the safety, scientific integrity, and accuracy of the clinical trials and disclosures supporting Madrigal’s lead product. In his telling, he did what the company expected of a senior clinical-development executive, then faced punishment for raising objections inside the organization.
The lawsuit alleges that Madrigal retaliated after he voiced concerns tied to safety issues involving the drug used for patients with MASH. No details beyond that general allegation are included in the material available here, and the filing itself has not been tested in court. Still, the accusation is consequential because it reaches beyond one executive’s departure. It raises questions about how a company handles dissent when the dissent comes from a physician responsible for clinical development.
In drug development, internal disagreement is not automatically a sign of wrongdoing. In a company marketing an approved therapy for chronic liver disease, however, the stakes are unusually high. Safety concerns can affect labeling, prescriber confidence, postmarketing surveillance, and the credibility of the evidence base that supported approval in the first place.
Why MASH drug safety disputes carry unusual weight
MASH is a progressive liver disease, and treatment decisions often rely on a narrow balance between benefit and risk. Approved therapies in this setting are scrutinized not only for efficacy but also for adverse effects that may compound a patient’s already complex metabolic and hepatic burden. When a senior clinical executive alleges that safety concerns were mishandled internally, the dispute immediately becomes more than an employment matter.
It becomes a test of whether the company’s scientific guardrails held firm when commercial and regulatory pressures collided with clinical caution.
That is especially sensitive for a medication positioned as Madrigal’s flagship product. A company’s lead therapy often anchors investor expectations, corporate strategy, and regulatory reputation. Any suggestion that adverse signals or trial-disclosure decisions were minimized can reverberate well beyond the executive suite, even if the allegations remain unproven.
Charlton’s complaint also points to federal whistleblower-protection statutes, a legal route designed to shield employees who surface concerns tied to safety or compliance. Those statutes are central in biomedical industries, where insiders are often the first to notice inconsistencies in safety interpretation, reporting practices, or the handling of risk information.
The clinical-development role at the center of the dispute
The lawsuit draws attention to the authority vested in the head of clinical development. In a pharmaceutical company, that position sits at the intersection of trial design, safety review, medical interpretation, and disclosure. A physician in that role is not simply reading data; he or she is helping decide how those data are translated into the public record, regulatory communications, and clinical messaging.
Charlton’s tenure, spanning roughly 15 months, was brief but highly relevant. The complaint says he moved into the role in October 2024 and left in January 2026 after the alleged conflict escalated. The precise internal events that led to the resignation are not available in the source material, but the legal theory is straightforward: a senior medical officer says he was forced out after pressing the company on safety-related issues.
In pharmacovigilance terms, the allegation is serious because it suggests a possible breakdown in internal escalation. If a company discourages or penalizes review of safety concerns, even indirectly, the consequence can be delayed corrective action and weakened confidence in later disclosures. If the company instead can show that the departure was unrelated to his objections, the legal and scientific implications would be very different. The lawsuit alone cannot resolve that question.
What the filing means for Rezdiffra’s public profile
Rezdiffra sits at the center of Madrigal’s commercial and clinical identity, which makes any safety-related litigation particularly sensitive. For physicians caring for patients with MASH, trust in a therapy depends not only on the label but on confidence that adverse events, uncertainties, and trial limitations were handled transparently.
A dispute like this can affect that trust even before any court findings emerge. It may prompt closer attention from prescribers, investors, regulators, and competing analysts watching how the company responds. The immediate issue is not whether the drug is safe or unsafe based on this filing; no such conclusion can be drawn from the limited material here. The immediate issue is whether the company adequately protected the internal scientific process when a senior physician says he raised concerns.
The case also reflects a broader reality in specialty therapeutics: when a company’s leading product treats a chronic disease with limited treatment options, any allegation touching safety management becomes magnified. Patients and clinicians rely on the assumption that adverse signals are examined without favoritism and that medical judgment can override corporate discomfort. The lawsuit asserts the opposite happened here.
What remains unresolved in the court filing
The available material does not describe the specific safety issues Charlton raised, the timing of those concerns, or how Madrigal responded internally. It also does not include the company’s defense, if one has been filed. Those omissions matter because they limit what can be said responsibly about the dispute itself.
For now, the case is an allegation of retaliation, not a judicial finding. The complaint seeks reinstatement or monetary damages, but the central clinical question will remain the same regardless of the legal outcome: how a company with an approved liver-disease therapy handles internal warnings when the people raising them are the physicians charged with protecting trial integrity and patient safety.
The lawsuit leaves that question open, and the answer will depend on what emerges in court records, not on the complaint alone.